{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:39:17Z","timestamp":1794335957027,"version":"4.9.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ijantimicag.2022.106708","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T11:13:56Z","timestamp":1672658036000},"page":"106708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8811-195X","authenticated-orcid":false,"given":"Daniele","family":"Focosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9997-5278","authenticated-orcid":false,"given":"Scott","family":"McConnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7276-7786","authenticated-orcid":false,"given":"Shmuel","family":"Shoham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Casadevall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2022.106708_bib0001","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0002","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1002\/1873-3468.12827","article-title":"RNA-virus proteases counteracting host innate immunity","volume":"591","author":"Lei","year":"2017","journal-title":"FEBS Letters"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0003","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0004","unstructured":"Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2\/3 EPIC-HR Study. Accessed online at https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-novel-covid-19-oral-antiviral-treatment-candidate on June 27, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00388-21","article-title":"Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays in infected, recovered, and vaccinated groups","volume":"59","author":"Narasimhan","year":"2021","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0006","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0007","unstructured":"Small Molecule of The Year, 2022. Accessed at https:\/\/drughunter.com\/small-molecule-of-the-year-2021\/?utm_source=rss&utm_medium=rss&utm_campaign=small-molecule-of-the-year-2021 on June 27, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0008","unstructured":"Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate. Accessed at https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-seeks-emergency-use-authorization-novel-covid-19 on June 27, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0009","unstructured":"Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment. Accessed online at https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-receives-us-fda-emergency-use-authorization-novel on June 27, 20022 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0010","unstructured":"Israel Authorizes Use of Pfizer Antiviral COVID Pill Paxlovid. Accessed online at https:\/\/www.haaretz.com\/israel-news\/israel-authorizes-use-of-pfizer-antiviral-covid-pill-paxlovid-1.10495082 on June 27, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0011","unstructured":"Oral COVID-19 antiviral, Paxlovid, approved by UK regulator. Accessed online at https:\/\/www.gov.uk\/government\/news\/oral-covid-19-antiviral-paxlovid-approved-by-uk-regulator on June 27, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0012","unstructured":"COVID-19: EMA recommends conditional marketing authorisation for Paxlovid. Accessed online at https:\/\/www.ema.europa.eu\/en\/news\/covid-19-ema-recommends-conditional-marketing-authorisation-paxlovid on June 27, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0013","unstructured":"The State Food and Drug Administration approved Pfizer's new coronavirus treatment drug neimatevir tablet\/ritonavir tablet combination package for import registration under emergency conditions [translated from Chinese]. Accessed online at https:\/\/www.nmpa.gov.cn\/yaowen\/ypjgyw\/20220212085753142.html on June 27, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0014","unstructured":"Pfizer Initiates Phase 2\/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants. Accessed online at https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-initiates-phase-23-study-novel-covid-19-oral on June 27, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0015","unstructured":"Pfizer Shares Top-Line Results from Phase 2\/3 EPIC-PEP Study of PAXLOVID\u2122 for Post-Exposure Prophylactic Use. Accessed at https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-top-line-results-phase-23-epic-pep-study on June 27, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0016","unstructured":"Pfizer Reports Additional Data on PAXLOVID\u2122 Supporting Upcoming New Drug Application Submission to U.S. FDA. Accessed at https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-reports-additional-data-paxlovidtm-supporting on June 27, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0017","unstructured":"Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID\u2122. Accessed online at https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-submission-new-drug-application-us-fda on July 1, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0018","article-title":"Case Report of Breakthrough Long COVID and the Use of Nirmatrelvir-Ritonavir","author":"Geng","year":"2022","journal-title":"In: ResearchSquare, editor"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0019","first-page":"95","article-title":"Effect of oral nirmatrelvir on Long COVID symptoms: 4 Cases and Rationale for Systematic Studies","volume":"7","author":"Peluso","year":"2022","journal-title":"Pathog Immun"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0020","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.cell.2022.01.014","article-title":"Multiple early factors anticipate post-acute COVID-19 sequelae","volume":"185","author":"Su","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0021","first-page":"ciac722","article-title":"Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae","author":"Swank","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.ijantimicag.2022.106708_bib0022","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cmi.2022.03.030","article-title":"Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19","volume":"28","author":"Girardin","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0023","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0140-6736(21)02657-X","article-title":"Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management","volume":"399","author":"Heskin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0024","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.42140","article-title":"Prevalence of contraindications to nirmatrelvir-ritonavir among hospitalized patients with COVID-19 at risk for progression to severe disease","volume":"5","author":"Hoertel","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0025","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01229-22","article-title":"Pharmacokinetics of nirmatrelvir and ritonavir in COVID-19 patients with end stage renal disease on intermittent haemodialysis","volume":"66","author":"Lingscheid","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.ijantimicag.2022.106708_bib0026","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2215\/CJN.05270522","article-title":"Prescribing nirmatrelvir\/ritonavir (Paxlovid) for COVID-19 in advanced CKD","volume":"17","author":"Hiremath","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0027","article-title":"Early experience with modified dose nirmatrelvir\/ritonavir in dialysis patients with coronavirus","author":"Brown","year":"2022","journal-title":"disease-2019"},{"issue":"11","key":"10.1016\/j.ijantimicag.2022.106708_bib0028","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","article-title":"Monoclonal antibody therapies against SARS-CoV-2","volume":"22","author":"Focosi","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.ijantimicag.2022.106708_bib0029","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc2214302","article-title":"Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB","volume":"388","author":"Imai","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0030","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","author":"Wang","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101972","article-title":"Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants","volume":"298","author":"Greasley","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0032","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMc2207519","article-title":"Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants","volume":"387","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0033","author":"Dabrowska","year":"2021","journal-title":"Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41422-022-00619-9","article-title":"Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates","volume":"32","author":"Bojkova","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0036","article-title":"Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2","volume":"205","author":"Ohashi","year":"2022","journal-title":"Antiviral Res Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0037","author":"Rai","year":"2022","journal-title":"Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of Concern"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0038","author":"Rosales","year":"2022","journal-title":"Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0039","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMc2201933","article-title":"Efficacy of antiviral agents against the SARS-CoV-2 Omicron Subvariant BA.2","volume":"386","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0040","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.chom.2022.10.003","article-title":"Virological characteristics of the SARS-CoV-2 Omicron BA.2.75","volume":"30","author":"Saito","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0041","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-022-04856-1","article-title":"Characterization and antiviral susceptibility of SARS-CoV-2 Omicron\/BA.2","volume":"607","author":"Uraki","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0042","article-title":"Paxlovid-like nirmatrelvir\/ritonavir fails to block SARS-CoV-2 transmission in ferrets","author":"Cox","year":"2022","journal-title":"bioRxiv"},{"issue":"9","key":"10.1016\/j.ijantimicag.2022.106708_bib0043","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2204919","article-title":"Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge","volume":"387","author":"Arbel","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0044","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(22)01586-0","volume":"400","author":"Wong","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0045","doi-asserted-by":"crossref","unstructured":"Dryden-Peterson S, Kim A, Kim AY, Caniglia EC, Lennes I, Patel R, et\u00a0al. Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system. medRxiv 2022;2022.06.14.22276393.","DOI":"10.1101\/2022.06.14.22276393"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0046","first-page":"830","article-title":"Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022","volume":"71","author":"Malden","year":"2022","journal-title":"MMWR"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0047","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3390\/vaccines10101731","article-title":"Nirmatrelvir\/ritonavir and molnuipiravir in the treatment of mild\/moderate COVID-19: results of a real-life study","volume":"10","author":"Gentile","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0048","author":"Zhou","year":"2022","journal-title":"Real-World effectiveness of nirmatrelvir\/ritonavir in preventing hospitalization among patients with COVID-19 at high risk for severe disease in the United States: A Nationwide Population-Based Cohort Study"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0049","author":"Aggarwal","year":"2022","journal-title":"Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during the emergence of Omicron variants BA.2\/BA2.12.1"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0050","author":"Schwartz","year":"2022","journal-title":"Real-world effectiveness of nirmatrelvir\/ritonavir use for COVID-19: A population-based cohort study in Ontario, Canada"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0051","article-title":"Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes","author":"Bajema","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0052","author":"Sedova","year":"2022","journal-title":"Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populations"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0053","author":"Hu","year":"2022","journal-title":"Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0054","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1021\/acs.biochem.2c00489","article-title":"Predicting antiviral resistance mutations in SARS-CoV-2 main protease with computational and experimental screening","volume":"61","author":"Sasi","year":"2022","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0055","author":"Noske","year":"2022","journal-title":"Structural basis of nirmatrelvir and ensitrelvir resistance profiles against SARS-CoV-2 Main Protease naturally occurring polymorphisms"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0056","author":"Moghadasi","year":"2022","journal-title":"Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0057","author":"Iketani","year":"2022","journal-title":"The functional landscape of SARS-CoV-2 3CL Protease"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0058","author":"Zhou","year":"2022","journal-title":"Nirmatrelvir resistant SARS-CoV-2 variants with high fitness in vitro"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0059","author":"Jochmans","year":"2022","journal-title":"The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0060","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0061","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMc2206449","article-title":"Rebound of SARS-CoV-2 infection after nirmatrelvir-ritonavir treatment","volume":"387","author":"Charness","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0062","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.cmi.2022.06.029","article-title":"Virological and clinical rebounds of COVID-19 soon after nirmatrelvir\/ritonavir discontinuation","volume":"28","author":"Antonelli","year":"2022","journal-title":"Clin Microb Infect"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0063","first-page":"ciac512","article-title":"Virologic characterization of symptom rebound following nirmatrelvir-ritonavir treatment for COVID-19","author":"Boucau","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0064","first-page":"ciac496","article-title":"Virologic and immunologic characterization of COVID-19 recrudescence after nirmatrelvir\/ritonavir treatment","author":"Carlin","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ijantimicag.2022.106708_bib0065","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jinf.2022.06.011","article-title":"COVID-19 \"Rebound\" associated with nirmatrelvir\/ritonavir pre-hospital therapy","volume":"85","author":"Coulson","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0066","first-page":"ciac663","article-title":"Clinical, virologic, and immunologic evaluation of symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir\/Ritonavir Treatment","author":"Epling","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0067","first-page":"e26239","volume":"14","author":"Alshanqeeti","year":"2022","journal-title":"COVID-19 rebound after Paxlovid treatment: A Case Series and Review of Literature Cureus"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0068","unstructured":"COVID-19 Rebound After Paxlovid Treatment. Accessed online at https:\/\/emergency.cdc.gov\/han\/2022\/pdf\/CDC_HAN_467.pdf on June 27, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0069","year":"2022","journal-title":"Fauci says he believes Paxlovid kept him out of the hospital, even though he tested positive again"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0070","unstructured":"Center for Drug Evaluation and Research (CDER) Review. Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir tables co-packaged with ritonavir tablets). Accessed online at https:\/\/www.fda.gov\/media\/155194\/download on May 1, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0071","doi-asserted-by":"crossref","unstructured":"Soares H, Baniecki M, Cardin R, Leister-Tebbe H, Zhu Y, Guan S, et\u00a0al. Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations. Research Square. 2022.","DOI":"10.21203\/rs.3.rs-1720472\/v2"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0072","author":"Deo","year":"2022","journal-title":"Viral and symptom rebound in untreated COVID-19 Infection"},{"issue":"24","key":"10.1016\/j.ijantimicag.2022.106708_bib0073","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1001\/jama.2022.9925","article-title":"From positive to negative to positive again-the mystery of why COVID-19 rebounds in some patients who take Paxlovid","volume":"327","author":"Rubin","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0074","author":"Fumagalli","year":"2022","journal-title":"Nirmatrelvir treatment blunts the development of antiviral adaptive immune responses in SARS-CoV-2 infected mice"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0075","first-page":"ciac481","article-title":"Rebound phenomenon after nirmatrelvir\/ritonavir treatment of Coronavirus Disease-2019 in high-risk persons","author":"Ranganath","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0076","author":"Wang","year":"2022","journal-title":"COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0077","author":"Dai","year":"2022","journal-title":"Viral kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron infection in mRNA-vaccinated individuals treated and not treated with nirmatrelvir-ritonavir"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0078","doi-asserted-by":"crossref","first-page":"e81849","DOI":"10.7554\/eLife.81849","article-title":"Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort study","author":"Hay","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0079","author":"Xu","year":"2022","journal-title":"COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0080","doi-asserted-by":"crossref","unstructured":"Pandit JA, Radin JM, Chiang D, Spencer EG, Pawelek JB, Diwan M, et\u00a0al. The Paxlovid Rebound Study: A prospective cohort study to evaluate viral and symptom rebound differences between Paxlovid and untreated COVID-19 Participants. 2022:2022.11.14.22282195.","DOI":"10.1101\/2022.11.14.22282195"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0081","unstructured":"Institute for Clinicala and Econimic Review (ICER). Special Assessment of Outpatient Treatments for COVID-19. Accessed online at https:\/\/icer.org\/wp-content\/uploads\/2021\/08\/ICER_COVID_19_Draft_Evidence_Report_020322.pdf on June 27, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0082","doi-asserted-by":"crossref","first-page":"ofab561","DOI":"10.1093\/ofid\/ofab561","article-title":"Estimation of Coronavirus Disease 2019 Hospitalization Costs From a Large Electronic Administrative Discharge Database, March 2020-July 2021","volume":"8","author":"Shrestha","year":"2021","journal-title":"Open forum infectious diseases"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0083","unstructured":"Drugs for Neglected Diseases initiative. Pfizer blocking research to generate evidence on optimal use of novel antiviral for COVID-19 patients in low- and middle-income countries. 15 Mar 2022. https:\/\/dndi.org\/press-releases\/2022\/pfizer-blocking-research-to-generate-evidence-optimal-use-novel-antiviral-covid19-low-and-middle-income-countries\/."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0084","unstructured":"Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries. Accessed online at https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-supply-unicef-4-million-treatment-courses-novel on June 27, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0085","unstructured":"Africa CDC has MOU with Pfizer for supplies of COVID-19 pill. Accessed online at https:\/\/www.reuters.com\/world\/africa\/africa-cdc-has-mou-with-pfizer-supplies-covid-19-pill-2022-03-10\/on June 27, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0086","unstructured":"Nod for Paxlovid's Indian generic version to take longer. Accessed online at https:\/\/economictimes.indiatimes.com\/industry\/healthcare\/biotech\/pharmaceuticals\/nod-for-paxlovids-indian-generic-version-to-take-longer\/articleshow\/89672841.cms on June 27, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0087","unstructured":"Drugmakers seem to be in no hurry to launch Covid antiviral pill Paxlovid. Accessed online at https:\/\/economictimes.indiatimes.com\/industry\/healthcare\/biotech\/pharmaceuticals\/drugmakers-seem-to-be-in-no-hurry-to-launch-covid-antiviral-pill-paxlovid\/articleshow\/92190063.cms on June 27, 2022."},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0088","doi-asserted-by":"crossref","first-page":"o1282","DOI":"10.1136\/bmj.o1282","article-title":"The black market for covid-19 antiviral drugs","volume":"377","author":"Plata","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0089","first-page":"825","article-title":"Dispensing of oral antiviral drugs for treatment of COVID-19 by Zip Code\u2013Level Social Vulnerability \u2014 United States, December 23, 2021\u2013May 21, 2022","volume":"72","author":"Gold","year":"2022","journal-title":"MMWR"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0090","year":"2022","journal-title":"dati settimanali 16-22 giugno (Lagevrio-Paxlovid). Accessed online at aifa.gov.it on June 29"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0091","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1080\/22221751.2022.2078230","article-title":"An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants","volume":"11","author":"Shen","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0092","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/microorganisms10071475","article-title":"The combination of molnupiravir with nirmatrelvir or GC376 has a synergic role in the inhibition of SARS-CoV-2 replication in vitro","volume":"10","author":"Gidari","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0093","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00697-22","article-title":"A randomized phase 2\/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: Results of the Phase 2a Part","volume":"66","author":"Mukae","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0094","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s13238-021-00883-2","article-title":"Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332","volume":"13","author":"Zhao","year":"2022","journal-title":"Protein Cell"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0095","author":"Greasley","year":"2022","journal-title":"Structural basis for Nirmatrelvir in vitro efficacy against the Omicron variant of SARS-CoV-2"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128629","article-title":"Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir","volume":"62","author":"Ullrich","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0097","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/s41598-022-05424-3","article-title":"Pro108Ser mutation of SARS-CoV-2 3CLpro reduces the enzyme activity and ameliorates the clinical severity of COVID-19","volume":"12","author":"Abe","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0098","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41422-022-00640-y","article-title":"The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition","volume":"32","author":"Sacco","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.ijantimicag.2022.106708_bib0099","author":"de Oliveira","year":"2022","journal-title":"H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS CoV-2 main protease through a nonnative hydrogen bond"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922002400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922002400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:44:44Z","timestamp":1760377484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857922002400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0924857922002400"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106708","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106708","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106708"}}